Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design, today announced a collaboration and license agreement with Eli Lilly and ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly for molecular glue therapeutics.

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

Eli Lilly and Co. to discover, develop and commercialize molecular glue therapeutics for oncology. “It’s a really important deal, especially given the discovery of Trueglues is something Magnet is ...

Massachusetts, USA-based start-up Magnet Biomedicine, which is advancing molecular glue discovery with rational selection and ...

Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license ...

Magnet Biomedicine, a biotechnology company advancing molecular glue discovery through rational selection and design, has selected Simplicis's Ledger™ platform after a rigorous evaluation process that ...